Curis Inc (CRIS) Files Form 4 Insider Selling : Martyn D Greenacre Sells 15,000 Shares

Curis Inc (CRIS): Martyn D Greenacre , director of Curis Inc sold 15,000 shares on May 27, 2016. The Insider selling transaction was reported by the company on May 27, 2016 to the Securities and Exchange Commission. The shares were sold at $1.69 per share for a total value of $25,350.00 , the company said in a SEC Form 4 Filing.

Other Insider transactions have been reported by the company according to SEC Form 4, on May 27, 2016, Kenneth I Kaitin (director) sold 15,000 shares at $1.76 per share price.On Dec 30, 2015, Daniel R Passeri (director) sold 25,600 shares at $2.96 per share price.

Curis: On Wednesday, May 25, 2016 heightened volatility was witnessed in Curis which led to swings in the share price. The shares opened for trading at $1.79 and hit $1.84 on the upside , eventually ending the session at $1.8, with a gain of 2.27% or 0.04 points. The heightened volatility saw the trading volume jump to 4,03,004 shares. The 52-week high of the share price is $3.75 and the company has a market cap of $233 M . The 52-week low of the share price is at $1.25.

Curis Money Flow Index Chart

Company has been under the radar of several Street Analysts.Curis is Initiated by Sun Trust Rbsn Humphrey to Buy and the brokerage firm has set the Price Target at $3. The Rating was issued on Mar 2, 2016.

Curis Inc. (Curis) is a biotechnology company. The Company is engaged in the development and commercialization drug candidates for the treatment of human cancers. The Company’s drug candidate CUDC-907 is an orally available small molecule inhibitor of histone deacetylase (HDAC) and phosphatidylinositol-3-kinase (PI3K) enzymes. Curis’ product pipeline also includes CUDC-427 an orally available small molecule antagonist of inhibitor of apoptosis (IAP) proteins. CUDC-907 is in Phase I clinical trial stage for the treatment of advanced lymphomas and multiple myeloma and human epidermal growth factor receptor 2 (HER 2-) estrogen-receptor-positive (ER+) or progesterone-receptor-positive (PR+) breast cancer and NUT midline carcinoma. CUDC-427 is in Phase I clinical trial stage for the treatment of advanced solid tumor and lymphomas. The Company’s PD-L1 antagonist and IRAK4 Inhibitor drug candidates are in preclinical stage of development.

Leave a Reply

Curis - Is it time to Sell?

Top Brokerage Firms are advising their investors on Curis. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.